Kieron M. Dunleavy, M.D.
Kieron M. Dunleavy, M.D.
Staff Clinician

Center for Cancer Research
National Cancer Institute

Building 10 - Magnuson Clinical Center, Room 4N115
Bethesda, MD 20892
301-435-1007

Dr. Dunleavy is the clinical director of the Lymphoid Malignancies Branch. He is a graduate of University College Dublin (UCD) Medical School and following a medical oncology fellowship at NCI, joined the Lymphoid Malignancies Branch where his research is focused on developing novel therapies for lymphoma and other lymphoid diseases. He is the principal investigator of a national multi-institutional study testing risk-adapted therapy in Burkitt lymphoma – this study includes c-MYC positive diffuse large B-cell lymphoma. His research also focuses on investigating new approaches in subtypes of DLBCL such as primary central nervous system lymphoma.

Areas of Expertise
lymphoma, lymphoproliferative disorders, lymphomatoid granulomatosis, HIV-associated lymphoma, novel therapies, adolescent lymphomas
Selected Publications
  1. Dunleavy K, Pittaluga S, Czuczman MS, Dave SS, Wright G, Grant N, Shovlin M, Jaffe ES, Janik JE, Staudt LM, Wilson WH.
    Blood. 113: 6069-76, 2009. [ Journal Article ]
  2. Dunleavy K, Hakim F, Kim HK, Janik JE, Grant N, Nakayama T, White T, Wright G, Kwak L, Gress R, Tosato G, Wilson WH.
    Blood. 106: 795-802, 2005. [ Journal Article ]
  3. Dunleavy K, Pittaluga S, Shovlin M, Steinberg SM, Cole D, Grant C, Widemann B, Staudt LM, Jaffe ES, Little RF, Wilson WH.
    N. Engl. J. Med.. 369: 1915-25, 2013. [ Journal Article ]
  4. Dunleavy K, Pittaluga S, Maeda LS, Advani R, Chen CC, Hessler J, Steinberg SM, Grant C, Wright G, Varma G, Staudt LM, Jaffe ES, Wilson WH.
    N. Engl. J. Med.. 368: 1408-16, 2013. [ Journal Article ]
  5. Dunleavy K, Little RF, Pittaluga S, Grant N, Wayne AS, Carrasquillo JA, Steinberg SM, Yarchoan R, Jaffe ES, Wilson WH.
    Blood. 115: 3017-24, 2010. [ Journal Article ]

Dr. Dunleavy was appointed Attending Staff Clinician at NCI in March 2006. He graduated from University College Dublin Medical School in 1994 and completed his residency and fellowship training at the Mater and St. James's Hospitals, Dublin, before coming to NCI in 2002 for a fellowship in Medical Oncology. Having completed his fellowship in February 2006, he was appointed to the position of Investigator/Attending Physician with the Metabolism Branch. Dr. Dunleavy has authored and helped translate from bench to bedside several clinical trials and is both a Principal Investigator and Co-Investigator on numerous trials in lymphoma. He plans to continue working as a clinical researcher, focusing on lymphoid malignancies. Dr. Dunleavy's goal is to continue to work in a collaborative capacity with the scientific community at NIH and apply novel discoveries and insights into the mechanisms and causes of lymphoid cancers in developing innovative therapies to combat these diseases.

Name Position
Joan Aaron R.N. Nurse Specialist
Andrea Lucas R.N. Clinical Research Nurse
Margaret (Peggy) Shovlin R.N., B.S.N., O.C.N. Clinical Research Nurse

Summary

Dr. Dunleavy is the clinical director of the Lymphoid Malignancies Branch. He is a graduate of University College Dublin (UCD) Medical School and following a medical oncology fellowship at NCI, joined the Lymphoid Malignancies Branch where his research is focused on developing novel therapies for lymphoma and other lymphoid diseases. He is the principal investigator of a national multi-institutional study testing risk-adapted therapy in Burkitt lymphoma – this study includes c-MYC positive diffuse large B-cell lymphoma. His research also focuses on investigating new approaches in subtypes of DLBCL such as primary central nervous system lymphoma.

Areas of Expertise
lymphoma, lymphoproliferative disorders, lymphomatoid granulomatosis, HIV-associated lymphoma, novel therapies, adolescent lymphomas

Clinical Trials

Publications

Selected Publications
  1. Dunleavy K, Pittaluga S, Czuczman MS, Dave SS, Wright G, Grant N, Shovlin M, Jaffe ES, Janik JE, Staudt LM, Wilson WH.
    Blood. 113: 6069-76, 2009. [ Journal Article ]
  2. Dunleavy K, Hakim F, Kim HK, Janik JE, Grant N, Nakayama T, White T, Wright G, Kwak L, Gress R, Tosato G, Wilson WH.
    Blood. 106: 795-802, 2005. [ Journal Article ]
  3. Dunleavy K, Pittaluga S, Shovlin M, Steinberg SM, Cole D, Grant C, Widemann B, Staudt LM, Jaffe ES, Little RF, Wilson WH.
    N. Engl. J. Med.. 369: 1915-25, 2013. [ Journal Article ]
  4. Dunleavy K, Pittaluga S, Maeda LS, Advani R, Chen CC, Hessler J, Steinberg SM, Grant C, Wright G, Varma G, Staudt LM, Jaffe ES, Wilson WH.
    N. Engl. J. Med.. 368: 1408-16, 2013. [ Journal Article ]
  5. Dunleavy K, Little RF, Pittaluga S, Grant N, Wayne AS, Carrasquillo JA, Steinberg SM, Yarchoan R, Jaffe ES, Wilson WH.
    Blood. 115: 3017-24, 2010. [ Journal Article ]

Biography

Dr. Dunleavy was appointed Attending Staff Clinician at NCI in March 2006. He graduated from University College Dublin Medical School in 1994 and completed his residency and fellowship training at the Mater and St. James's Hospitals, Dublin, before coming to NCI in 2002 for a fellowship in Medical Oncology. Having completed his fellowship in February 2006, he was appointed to the position of Investigator/Attending Physician with the Metabolism Branch. Dr. Dunleavy has authored and helped translate from bench to bedside several clinical trials and is both a Principal Investigator and Co-Investigator on numerous trials in lymphoma. He plans to continue working as a clinical researcher, focusing on lymphoid malignancies. Dr. Dunleavy's goal is to continue to work in a collaborative capacity with the scientific community at NIH and apply novel discoveries and insights into the mechanisms and causes of lymphoid cancers in developing innovative therapies to combat these diseases.

Team

Name Position
Joan Aaron R.N. Nurse Specialist
Andrea Lucas R.N. Clinical Research Nurse
Margaret (Peggy) Shovlin R.N., B.S.N., O.C.N. Clinical Research Nurse